Literature DB >> 10550852

Elevated plasma levels of clozapine after concomitant use of fluvoxamine.

M Heeringa1, R Beurskens, W Schouten, M M Verduijn.   

Abstract

Selective serotonin reuptake inhibitors can be added to clozapine therapy in order to treat remaining negative symptoms and obsessive compulsive symptoms. The present case report describes a 44-year-old man exhibiting extremely elevated plasma levels of clozapine after the addition of fluvoxamine, up to 4160 mcg/l. The elevated plasma levels of clozapine, which were discovered 6 months after the SSRI was added, is likely to be caused by a drug-drug interaction. Clozapine is a substrate of CYP 1A2 and is predominantly metabolised in the liver. Of the SSRIs, fluvoxamine is one of the most potent inhibitors of the isoenzyme CYP 1A2. This case serves to emphasise the need for continuous attention to drug-drug interactions, especially when they might be easily overlooked due to the lack of clear symptoms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10550852     DOI: 10.1023/a:1008748110692

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  10 in total

1.  Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports.

Authors:  S A Chong; C H Tan; H S Lee
Journal:  J Clin Psychopharmacol       Date:  1997-02       Impact factor: 3.153

2.  Fluvoxamine-clozapine dose-dependent interaction.

Authors:  J S Markowitz; H S Gill; M Lavia; T D Brewerton; C L DeVane
Journal:  Can J Psychiatry       Date:  1996-12       Impact factor: 4.356

Review 3.  Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance.

Authors:  U Fuhr
Journal:  Drug Saf       Date:  1998-04       Impact factor: 5.606

4.  Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine.

Authors:  A Szegedi; J Wiesner; C Hiemke
Journal:  J Clin Psychopharmacol       Date:  1995-04       Impact factor: 3.153

5.  Elevated levels of clozapine in serum after addition of fluvoxamine.

Authors:  C Hiemke; H Weigmann; S Härtter; N Dahmen; H Wetzel; H Müller
Journal:  J Clin Psychopharmacol       Date:  1994-08       Impact factor: 3.153

Review 6.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Authors:  A Fitton; R C Heel
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

7.  Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service.

Authors:  M Jerling; L Lindström; U Bondesson; L Bertilsson
Journal:  Ther Drug Monit       Date:  1994-08       Impact factor: 3.681

Review 8.  The pharmacogenetics of the selective serotonin reuptake inhibitors.

Authors:  K Brøsen
Journal:  Clin Investig       Date:  1993-12

9.  Emergence of obsessive compulsive symptoms during treatment with clozapine.

Authors:  R W Baker; K N Chengappa; J W Baird; S Steingard; M A Christ; N R Schooler
Journal:  J Clin Psychiatry       Date:  1992-12       Impact factor: 4.384

10.  Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors.

Authors:  F Centorrino; R J Baldessarini; F R Frankenburg; J Kando; S A Volpicelli; J G Flood
Journal:  Am J Psychiatry       Date:  1996-06       Impact factor: 18.112

  10 in total
  11 in total

Review 1.  Treatment of the metabolic disturbances caused by antipsychotic drugs: focus on potential drug interactions.

Authors:  Trino Baptista; N M K Ng Ying Kin; Serge Beaulieu
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  A therapeutic interaction between cimetidine and clozapine: case study and review of the literature.

Authors:  Magdalena Watras; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2013-10

Review 3.  Interactions between the cytochrome P450 system and the second-generation antipsychotics.

Authors:  Trevor I Prior; Glen B Baker
Journal:  J Psychiatry Neurosci       Date:  2003-03       Impact factor: 6.186

Review 4.  The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review.

Authors:  Christoffer Polcwiartek; Jimmi Nielsen
Journal:  Psychopharmacology (Berl)       Date:  2015-12-02       Impact factor: 4.530

Review 5.  Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.

Authors:  D P Figgitt; K J McClellan
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

Review 6.  Fluvoxamine: a review of its therapeutic potential in the management of anxiety disorders in children and adolescents.

Authors:  S M Cheer; D P Figgitt
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 7.  Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?

Authors:  Gary Remington; Ofer Agid; George Foussias; Larissa Ferguson; Krysta McDonald; Valerie Powell
Journal:  Psychopharmacology (Berl)       Date:  2012-11-22       Impact factor: 4.530

8.  Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia.

Authors:  Norio Yasui-Furukori; Tsuyoshi Kondo; Kazuo Mihara; Yoshimasa Inoue; Sunao Kaneko
Journal:  Psychopharmacology (Berl)       Date:  2003-09-04       Impact factor: 4.530

9.  Ciprofloxacin and Clozapine: A Potentially Fatal but Underappreciated Interaction.

Authors:  Jonathan M Meyer; George Proctor; Michael A Cummings; Laura J Dardashti; Stephen M Stahl
Journal:  Case Rep Psychiatry       Date:  2016-10-30

Review 10.  Antidepressants- and antipsychotics-induced hepatotoxicity.

Authors:  Nevena Todorović Vukotić; Jelena Đorđević; Snežana Pejić; Neda Đorđević; Snežana B Pajović
Journal:  Arch Toxicol       Date:  2021-01-05       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.